What is US Patent 8,129,343 about (and why it matters for semaglutide)?
US Patent 8,129,343 is listed as a patent covering a semaglutide-related invention, which is relevant to how long patent protection can delay certain generic or biosimilar versions of semaglutide in the U.S. Patent term timing depends on filing dates and how the patent is scheduled to expire (including any adjustments). Public listings and aggregators such as DrugPatentWatch track these schedules for specific patents tied to branded products. [1]
When does US Patent 8,129,343 expire?
DrugPatentWatch tracks the expiration date for individual patents tied to semaglutide, including US 8,129,343. You can check the exact expiration date on its patent page here: https://www.drugpatentwatch.com/p/US8129343 [1]
Because patent expiration dates can vary by patent-prosecution details and any granted term adjustments, the most reliable single “expiration date” figure is the one listed for that specific patent on the patent-tracking record. [1]
Does patent expiration alone determine when generics/biosimilars can launch?
No. Even after a patent expires, other forms of protection can still delay market entry, such as:
- other patents covering the drug substance, formulation, devices, or dosing regimens
- regulatory exclusivities tied to approval (which are not the same thing as patent terms)
- patent litigation (or settlements) that can extend practical delay beyond the scheduled expiration
So, for semaglutide, the “earliest” launch date for a competitor typically requires looking across the full patent landscape, not just US 8,129,343. DrugPatentWatch compiles these patent timelines to help with that comparison. [1]
Where can I verify the exact expiration date for US 8,129,343?
Use the dedicated DrugPatentWatch record for US 8,129,343, which shows the expiration schedule used by patent-watch trackers: https://www.drugpatentwatch.com/p/US8129343 [1]
Sources
- DrugPatentWatch – US8129343 (Semaglutide-related patent)